Elmind Capital LP purchased a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX – Free Report) during the second quarter, Holdings Channel reports. The firm purchased 4,550,000 shares of the biotechnology company’s stock, valued at approximately $17,062,500,000. CytomX Therapeutics comprises 4.3% of Elmind Capital LP’s portfolio, making the stock its 9th biggest holding.
Other hedge funds have also recently bought and sold shares of the company. AWM Investment Company Inc. bought a new position in shares of CytomX Therapeutics during the second quarter valued at $562,000. ADAR1 Capital Management LLC bought a new stake in shares of CytomX Therapeutics in the 2nd quarter worth about $12,619,000. Hsbc Holdings PLC bought a new stake in shares of CytomX Therapeutics in the 2nd quarter worth about $103,000. Canada Pension Plan Investment Board acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $531,000. Finally, Legal & General Group Plc acquired a new stake in shares of CytomX Therapeutics during the 2nd quarter worth about $462,000. 67.77% of the stock is currently owned by institutional investors and hedge funds.
CytomX Therapeutics Stock Performance
Shares of CTMX opened at $3.37 on Wednesday. The firm has a market capitalization of $734.32 million, a price-to-earnings ratio of -6.74 and a beta of 2.12. The business’s fifty day moving average price is $3.43 and its two-hundred day moving average price is $4.07. CytomX Therapeutics, Inc. has a 52 week low of $1.90 and a 52 week high of $8.21.
Wall Street Analysts Forecast Growth
CTMX has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Tuesday, June 16th. Zacks Research cut CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Wolfe Research started coverage on CytomX Therapeutics in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating on the stock in a research note on Thursday, August 13th. Finally, Wall Street Zen lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CytomX Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $11.90.
Get Our Latest Stock Analysis on CytomX Therapeutics
CytomX Therapeutics Profile
CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.
At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.
Featured Stories
- Five stocks we like better than CytomX Therapeutics
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX – Free Report).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
